Bank of America Upgrades Globus Medical (NYSE:GMED) to “Neutral”
Globus Medical (NYSE:GMED – Get Free Report) was upgraded by investment analysts at Bank of America from an “underperform” rating to a “neutral” rating in a research note issued to investors on Thursday,Benzinga reports. The firm presently has a $97.00 target price on the medical device company’s stock, up from their prior target price of […]
9 Jan 09:22 · The Cerbat Gem